Related Experiment Video

Updated: May 30, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth

Chen Huang1, Guang Yang, Tao Jiang

  • 1Department of General Surgery, Affiliated First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.

World Journal of Gastroenterology
|July 30, 2011
PubMed
Abstract

Insights

Silencing signal transducer and activator of transcription 3 (STAT3) using RNA interference inhibited pancreatic cancer cell growth and tumor formation. This suggests STAT3 gene silencing is a potential therapeutic strategy for pancreatic cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is implicated in various cancers.
  • STAT3 signaling is crucial for cell proliferation and survival in pancreatic cancer.

Purpose of the Study:

  • To investigate the therapeutic potential of RNA interference (RNAi) mediated STAT3 gene silencing.
  • To evaluate the impact of STAT3 inhibition on human pancreatic cancer growth in vitro and in vivo.

Main Methods:

  • STAT3 specific shRNA was employed to silence STAT3 expression in the SW1990 pancreatic cancer cell line.
  • In vitro anti-growth effects were assessed, alongside in vivo studies using experimental cancer xenografts in nude mice.
  • STAT3 signaling pathway components were analyzed using reverse transcription polymerase chain reaction and western blotting.

Main Results:

  • RNAi effectively inhibited STAT3 expression in SW1990 cells.
  • STAT3 silencing reduced cell proliferation, induced apoptosis, and decreased CyclinD1 and Bcl-xL levels.
  • In vivo, STAT3 inhibition suppressed SW1990 cell tumorigenicity and tumor growth.

Conclusions:

  • The STAT3 signaling pathway is vital for pancreatic cancer progression.
  • STAT3 gene silencing via RNAi presents a promising novel therapeutic approach for pancreatic cancer treatment.
Keywords:
GrowthPancreatic cancerRNA interferenceSignal transduction and activation of transcription 3

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...